Avoidance diets--how selective should we be?

S L Taylor; R K Bush; W W Busse

PubMed · 3475554

Avoidance diets--how selective should we be?

Abstract

Selective avoidance diets are the most common means of treatment for food allergies and other types of food sensitivities. With IgE-mediated food allergies, adverse reactions can occur in some patients to very small amounts of the offending food; therefore, strict avoidance of the offending food must be accomplished. With other, non-immunological types of food sensitivities, such as lactose intolerance and sulfite sensitivity, the patients are able to tolerate some, although variable, amounts of the offending substance. Thus, the degree of tolerance is an important concern in the construction of safe and effective avoidance diets. Another issue in the development of selective avoidance diets is the presence of the allergen in specific foods. For example, the peanut allergen is a protein which is not present in peanut oil. Consequently, peanut oil is safe to consume for peanut-allergic patients. Cross-reactivity is yet another concern in the development of selective avoidance diets. Cross reactions can occur between related species of legumes, crustacea, eggs, and milk for example. The construction of a safe and effective avoidance diet for food allergies and sensitivities requires consideration of several important issues and is a responsibility that should not be taken lightly.

Explore related subjects

Cross Reactions Food Food Hypersensitivity Food Preferences Humans Immune Tolerance Immunoglobulin E Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

S L Taylor, R K Bush, W W Busse. Avoidance diets--how selective should we be?. https://pubmed.ncbi.nlm.nih.gov/3475554/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay.

F2-Isoprostanes are stable lipid peroxidation products of arachidonic acid, the quantification of which provides an index of oxidative stress in vivo. We describe a method for analysing isoprostaglandin F2alpha type III (15-F2t-IsoP) in biological fluids. The method involves solid-phase extraction on octadecyl endcapped and aminopropyl cartridges. After conversion to trimethylsilyl ester trimethylsilyl ether derivatives, isoprostaglandin F2alpha type III is analysed by mass spectrometry, operated in electronic impact selected ion monitoring mode. We have compared enzyme immunoassay (EIA; Cayman, Ann Arbor, MI, USA) to this method with 30 human urine aliquots following the same extraction procedure in order to determine the agreement between both methods. Isoprostaglandin F2alpha type III concentrations determined with gas chromatography-mass spectrometry (GC-MS) did not agree with those determined with EIA. Our results suggest that GC-MS and EIA do not measure the same compounds. As a consequence, comparison of clinical results using GC-MS and EIA should be avoided.

Cross Reactions↗

PubMed2001

Urine drugs of abuse testing at the point-of-care: clinical interpretation and programmatic considerations with specific reference to the Syva Rapid Test (SRT).

We evaluated a new point-of-care (POC) device for urine drugs of abuse (DOA) screening including appropriate clinical interpretation and potential benefits in a large academic medical center. Two hundred consecutive urine samples were tested using Syva Rapid Test (SRT) and existing laboratory methods (Syva EMIT II). Agreement between methods was acceptable with some considerations. Threshold concentration differences, drug interferences, and cross-reactivity profiles of the class-specific assays resulted in performance differences between the POC and central laboratory methods. Clinical interpretation of POC results requires an understanding of these issues as well as the limitations of urine testing. While urine-based screening is used in workplace testing and in a variety of clinical applications, quantitative blood measurements of some drugs (e.g. ethanol, acetaminophen, salicylate, +/-tricyclic antidepressants) will remain important in the emergent setting. Performance of the SRT method takes approximately 10 min. Consequently, the major advantage over laboratory methods is rapid turnaround time. At the Massachusetts General Hospital, the most important application is for samples from the emergency department (about 1700/year). Each institution should assess its own needs and capabilities with regard to POC versus laboratory-based testing for DOA.

Cross Reactions↗

PubMed2001

A new ultrasensitive assay for quantitation of HIV-1 RNA in plasma.

Nucleic acid-based diagnostic assays for the quantitation of plasma HIV-1 RNA levels are used to monitor disease progression and the response of patients to antiretroviral drug therapy. The LCx HIV RNA Quantitative Assay (Abbott Laboratories, North Chicago, IL) is an assay for the quantitation of HIV type 1 RNA in plasma that uses competitive reverse transcription PCR (RT-PCR) followed by Microparticle Enzyme Immunoassay, and includes an internal control for inhibition and RNA recovery, that is taken through the entire sample preparation procedure. The performance of the assay was assessed for 1 and 0.2 ml sample volumes. For a 1 ml sample volume, the lower limit of detection was found to be 50 copies/ml with a linear range from 50 to 1 million copies/ml. For a 0.2 ml sample volume, the lower limit of detection was found to be 178 copies/ml with a linear range from 178 to 5 million copies/ml. The assay is able to detect and quantitate HIV subtypes A-G and group O. LCx HIV RNA assay quantitation results are highly correlated to the standard and ultrasensitive Amplicor HIV-1 Monitor assay (Roche Molecular Systems) quantitation results. Assay performance is consistent with the use of this test for routine quantitation of HIV-1 RNA in plasma.

Cross Reactions↗